Table 1.
Summary table of clinical characteristics of patient donors
| ID | Age | Sex | Stage | Chemotherapy regimen | TRG | Differentiation |
|---|---|---|---|---|---|---|
| CAM298 | 58 | M | ypT1bN0M0 | ECX | 2 | Well |
| CAM388 | 78 | M | ypT2N0M0 | ECX | 4 | Moderate to poor |
| CAM247 | 67 | M | ypT2N2M0 | ECX | 4 | Moderate |
| CAM292 | 66 | F | ypT3N1MX | ECX | 4 | Moderate to poor |
| CAM296 | 72 | M | ypT3N3MX | ECF | 4 | Moderate to poor |
| CAM338 | 51 | F | ypT3N1MX | ECX | 5 | Moderate to poor |
| CAM401 | 77 | F | ypT4aN2M0 | CF | 5 | Poor |
| CAM412 | 52 | F | cT1bN0M0 | No chemotherapy | No chemotherapy | Poor |
| CAM277 | 80 | F | cT3N2M0 | No chemotherapy | No chemotherapy | Poor |
| CAM408 | 60 | M | cT1aN0M0 | No chemotherapy | No chemotherapy | Moderate |
The tumor regression grade (TRG) was used to describe histopathological response to chemotherapy, whereby 1 indicates complete regression and 5 is defined as no regressive changes. Patients are ranked by TRG
The acronyms for the chemotherapy regimens are: ECX Epirubicin, Oxaliplatin, Capecitabine, ECF Epirubicin, Cisplatin, 5-Flourouracil, EOX Epirubicin, Oxaliplatin, Capecitabine, and CF Cisplatin, Fluorouracil